NEW YORK (GenomeWeb) – Illumina and ArcherDx will collaborate on the development of in vitro diagnostics, the companies said today.
Under the terms of the agreement, ArcherDX will lead the development using its anchored multiplex PCR (AMP) chemistry to develop tests that will run on Illumina's MiSeqDx instrument.
The collaboration "enables our vision of creating a companion test aligned to the current and next generations of targeted therapies, rather than a single companion diagnostic targeting a single targeted therapy," ArcherDX CEO Jason Myers said in a statement. Myers added that the company plans to also work with pharmaceutical companies to bring a next-generation sequencing-based companion diagnostic through US Food and Drug Administration approval.
John Leite, vice president of market development for oncology at Illumina, said in a statement that the collaboration would enable "the development of companion diagnostics using NGS" and "expand IVD test offerings on the MiSeqDx."